1. Home
  2. SLVM vs CAPR Comparison

SLVM vs CAPR Comparison

Compare SLVM & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sylvamo Corporation

SLVM

Sylvamo Corporation

HOLD

Current Price

$38.44

Market Cap

1.7B

ML Signal

HOLD

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$6.61

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLVM
CAPR
Founded
1898
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Paper
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.6B
IPO Year
2021
2011

Fundamental Metrics

Financial Performance
Metric
SLVM
CAPR
Price
$38.44
$6.61
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
8
Target Price
$54.00
$44.63
AVG Volume (30 Days)
269.1K
5.7M
Earning Date
05-08-2026
05-12-2026
Dividend Yield
4.15%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,351,000,000.00
N/A
Revenue This Year
$0.93
N/A
Revenue Next Year
$1.54
$3.31
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$35.53
$2.96
52 Week High
$56.80
$40.37

Technical Indicators

Market Signals
Indicator
SLVM
CAPR
Relative Strength Index (RSI) 48.23 32.07
Support Level $36.78 $4.23
Resistance Level $40.13 $30.39
Average True Range (ATR) 1.52 0.81
MACD 0.05 0.38
Stochastic Oscillator 31.47 71.48

Price Performance

Historical Comparison
SLVM
CAPR

About SLVM Sylvamo Corporation

Sylvamo Corp is an uncoated papers company with a broad portfolio of top-tier brands and low-cost, large-scale paper mills. It produces uncoated freesheet (UFS) for paper products such as cut size and offset paper, as well as market pulp. The company offers Copy and Printer papers, Commercial Printing papers, Converting papers, and Specialty papers. It operates in three geographical segments: Europe, Latin America, and North America. Key revenue is generated from North America.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: